IngentaConnect Imiquimod 5% cream (Aldara)

Abstract:

Imiquimod is a novel synthetic molecule with potent immune-modifying activities. Formulated in a 5% vanishing cream as Aldara™ , this self-applied therapy has shown good efficacy and safety in the treatment of external genital and perianal warts caused by human papillomavirus (HPV) infection (Condyloma acuminata). The molecule does not demonstrate direct antiviral activity, but through induction of cytokines results in immune-based resolution of wart tissue and reduction of viral burden. Phase III trials of imiquimod have demonstrated that patients who experience complete clearance of either new or recalcitrant warts tend to remain clear, possibly related to Th1 immune recognition and memory. Self-application, good tolerability and a unique mechanism of action combine to make imiquimod a reasonable first-line therapy for genital warts. The effects of imiquimod on immune function suggest several potential uses. Preclinical studies of infection with herpes simplex virus (HSV), cutaneous leishmaniasis, Rift Valley Fever virus and vesiculostomatitis virus have shown reduced viral persistence, reduced recurrence (HSV) and diminished pathology (Leishmania donovani). In a murine tumour model using the FCB bladder cancer cell line, imiquimod behaves as a potent adjuvant leading to immune-based tumour cell eradication and immunity against subsequent FCB cell challenge. The ability of imiquimod to induce significant production of interferon alpha (IFN- agr ) by monocytes/macrophages suggests that diseases responsive to recombinant interferon therapy, such as basal cell carcinoma, may be reasonable clinical targets. The induction of tumour necrosis factor alpha (TNF- agr ), interferon gamma (IFN- ggr ) and interleukin-12 (IL-12) leads to inhibition of IL-5, with animal models demonstrating immune deviation away from Th2 immune responses. The observation that several patients with hepatitis C infection and eosinophilia showed normalisation of elevated eosinophil counts in association with oral imiquimod therapy encourages further exploration of the immune modifying properties of this novel molecule. This review is focused on the use of imiquimod for the treatment of external genital and perianal warts.

Keywords: adjuvants; Aldara; aminoquinolines; biological response modifiers; bladder neoplasms; clinical trial; Condylomata acuminata; cytokines; immunotherapy; immunological; interferon inducers; interferons; papillomavirus; imiquimod; immune deviation; immunostimulants

Document Type: Miscellaneous

Affiliations: 1: 13M Pharmaceuticals, Medical Affairs Building 270-3A-01, St Paul, MN 55144-1000, USA(Tel: +1 612 736 9302; Fax: +1 612 736 8165;Email: hbslade@mmm.com) 2: University of Pennsylvania, Immunology Section, Department of Pediatrics, CHOP, Pennsylvania, PA, USA 3: 3M Pharmaceuticals, Department of Pharmacology, St Paul, MN 55144-1000, USA

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$99.00 plus tax

Imiquimod 5% cream (Aldara™)